We are monitoring the impact of COVID-19 on Antibody Drug Conjugates Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 5792
Share on
Share on

Antibody Drug Conjugates Market Analysis – By pipeline (Phase, Mode of action( Igg1 antibodies, HER2 antibodies), Technology, linker), Technology (Seattle genetics, Immunogen, Immunomedics), End User(Research institutes, Hospitals, Clinics), Region - Industry Size, Share, Trends, Growth, Forecast | 2019 - 2024

Pulished: August, 2019
ID: 5792
Pages: 175

Antibody Drug Conjugates Market Size & Growth (2019 – 2024)

According to the report, the Global Antibody Drug Conjugates Market Size is valued at USD 11.8 Billion in 2019 and estimated to be growing at a CAGR of 24.74%, to reach USD 35.6 Billion by 2024.

MARKET OVERVIEW

Antidrug body conjugates are the drugs used to treat cancer patients. These are used to kill away the cancer cells present in the body. The U.S. FDA has accepted some of the Antibody-drug conjugates, and many more are on clinical trials, and this is one of the significant factors that drive the market. Especially the North America region is the most demanding market of antibody-drug conjugate. Cell Mosaic has invented new Antibody Mertansine conjugation kit with SMCC and DM1. This kit offers an easy and straightforward way for labelling the lgG with DM1.

Drivers

Factors that are responsible for the Antibody-drug conjugates market growth are lifestyle changes, growing occurrences of cancer, and also increasing advance technology. Increase of theoretical researches about the drug conjugates market is driving forward.

Pharmaceutical companies and biotechnology companies are joining together to form as one for the development of new novel drug discoveries, and this is propelling the market growth. The growing research on cancer-related diseases is also fueling the market.

Restrains

The cost related with the antibody-drug conjugates is so high that people can’t afford to buy, and strict rules and regulations to be followed during the time of approval of products are hindering the market growth. Shortage of funds also restrains the market growth.

Recent Market Developments in the Antibody Drug Conjugates Industry

  • On March 31, 2020, Oxford Biotherapeutics, a leading clinical-stage oncology industry that produces immune-oncology and antibody-drug conjugate based therapies, has made a public statement that they have chosen formal IND enabling studies.
  • On March 22, 2019, Takeda Pharmaceutical company and LegoChem Biosciences made an announcement that both the companies have agreed to become one for the development of antibody-drug conjugate for cancer therapies. 

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2018 – 2024

Base Year

2018

Forecast Period

2019 - 2024

Segments Covered

By Pipeline, Technology, End-User, Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.

 

This market research report on Global Antibody Drug Conjugates Market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2024.

Antibody Drug Conjugates Market - By Pipeline

  • Phase
  • Mode of action
    • Igg1 antibodies
    • HER2 antibodies
  • Technology
  • Linker

Antibody Drug Conjugates Market - By Technology

  • Seattle Genetics
  • Immunogen
  • Immunomedics

Antibody Drug Conjugates Market - By End User

  • Research institutes
  • Hospitals
  • Clinics

Regional Analysis

North America is dominating the global market due to the presence of large companies in this area and their high investment in the cancer product pipelines. Asia-Pacific is the fastest-growing region with a high CAGR owing to the rise in the prevalence of cancer and emerging economies like China and India.

List of Companies Operating the Global Antibody Drug Conjugate Market Profiled in the Report are:

  1. Seattle Genetics
  2. Genentech
  3. Takeda Pharmaceuticals
  4. Hoffmann-La Roche
  5. Bayer Healthcare
  6. Agensys, Inc.,
  7. Immunogen
  8. Novartis
  9. Oxford Biotherapeutics
  10. Synthon Biopharmaceuticals
  1. Introduction         
    1. Antibody Drug Conjugates Market Definition                    
    2. Study Deliverables                  
    3. Base Currency, Base Year and Forecast Periods  
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases                      
      1. Secondary Research           
      2. Primary Research 
      3. Econometric Modelling      
    3. Expert Validation
    4. Analysis of Design Study Timeline
  3. Overview 
    1. Executive Summary                
    2. Key Inferences 
    3. Epidemiology      
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)            
    1. Antibody Drug Conjugates Market Drivers  
    2. Antibody Drug Conjugates Market Restraints                    
    3. Key Challenges 
    4. Current Opportunities in the Antibody Drug Conjugates Market
  5. Antibody Drug Conjugates Market Segmentation
    1. Pipeline
      1. Introduction           
      2. Phase
      3. Mode of Action
        1. IgG1 Antibodies
        2. HER2 Antibodies
      4. Y-o-Y Growth Analysis, By Pipeline           
      5. Market Attractiveness Analysis, By Pipeline         
      6. Market Share Analysis, By Pipeline
    2. By Technology
      1. Seattle Genetics
      2. Immunogen
      3. Immunomedics
    3. End-User            
      1. Research institutes            
      2. Hospitals 
      3. Clinics       
      4. Others     
      5. Y-o-Y Growth Analysis, By End User             
      6. Market Attractiveness Analysis, By End User           
      7. Market Share Analysis, By End User
  6. Geographical Analysis                      
    1. Introduction 
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
        1. By Geographical Area
        2. By Pipeline
        3. By Technology
        4. By End-User
      4. Market Attractiveness Analysis
        1. By Geographical Area
        2. By Pipeline
        3. By Technology
        4. By End-User
      5. Market Share Analysis
        1. By Geographical Area
        2. By Pipeline
        3. By Technology
        4. By End-User
    2. North America  
      1. Introduction           
      2. United States         
      3. Canada
    3. Europe
      1. Introduction
      2. U.K
      3. Spain
      4. Germany 
      5. Italy
      6. France       
    4. Asia-Pacific
      1. Introduction
      2. China
      3. India
      4. Japan
      5. Australia
      6. South Korea           
    5. Latin America
      1. Introduction
      2. Brazil
      3. Argentina
      4. Mexico
      5. Rest of Latin America          
    6. Middle East & Africa
      1. Introduction
      2. Middle-East
      3. Africa         
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social         
      4. Technological         
      5. Legal          
      6. Environmental       
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers        
      2. Bargaining Power of Consumers
      3. The threat of New Entrants
      4. The threat of Substitute Products and Services              
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Seattle Genetics      
      1. Overview
      2. Product Analysis
      3. Financial analysis
      4. Recent Developments
      5. SWOT analysis
    2. Analyst View
      1. Genentech
      2. Takeda Pharmaceuticals 
      3. Hoffmann-La Roche 
      4. Bayer Healthcare
      5. Agensys, Inc
      6. Immunogen
      7. Novartis
      8. Oxford Biotherapeutic
      9. Synthon Biopharmaceuticals   
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities                 

Appendix

  1. List of Tables
  2. List of Figures      
  • Global and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms Technology along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Antibody Drug Conjugates  Market By Region, From 2019-2024 ( USD Billion )
  2. Global Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  3. Global Phase Market By Region, From 2019-2024 ( USD Billion )
  4. Global Mode of action Market By Region, From 2019-2024 ( USD Billion )
  5. Global Technology Market By Region, From 2019-2024 ( USD Billion )
  6. Global Linker Market By Region, From 2019-2024 ( USD Billion )
  7. Global Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  8. Global Research institutes Market By Region, From 2019-2024 ( USD Billion )
  9. Global Hospitals Market By Region, From 2019-2024 ( USD Billion )
  10. Global Clinics Market By Region, From 2019-2024 ( USD Billion )
  11. Global Others Market By Region, From 2019-2024 ( USD Billion )
  12. North America Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  13. North America Phase Market By Region, From 2019-2024 ( USD Billion )
  14. North America Mode of action Market By Region, From 2019-2024 ( USD Billion )
  15. North America Technology Market By Region, From 2019-2024 ( USD Billion )
  16. North America Linker Market By Region, From 2019-2024 ( USD Billion )
  17. North America Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  18. North America Research institutes Market By Region, From 2019-2024 ( USD Billion )
  19. North America Hospitals                    Market By Region, From 2019-2024 ( USD Billion )
  20. North America Clinics Market By Region, From 2019-2024 ( USD Billion )
  21. North America Others Market By Region, From 2019-2024 ( USD Billion )
  22. United States Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  23. United States Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  24. Canada Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  25. Canada Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  26. Europe Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  27. Europe Phase Market By Region, From 2019-2024 ( USD Billion )
  28. Europe Mode of action Market By Region, From 2019-2024 ( USD Billion )
  29. Europe Technology Market By Region, From 2019-2024 ( USD Billion )
  30. Europe Linker Market By Region, From 2019-2024 ( USD Billion )
  31. Europe Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  32. Europe Research institutes Market By Region, From 2019-2024 ( USD Billion )
  33. Europe Hospitals Market By Region, From 2019-2024 ( USD Billion )
  34. Europe Clinics Market By Region, From 2019-2024 ( USD Billion )
  35. Europe Others Market By Region, From 2019-2024 ( USD Billion )
  36. U.K. Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  37. U.K. Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  38. Germany Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  39. Germany Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  40. France Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  41. France Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  42. Italy Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  43. Italy Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  44. Spain Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  45. Spain Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  46. Asia Pacific Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  47. Asia Pacific Phase Market By Region, From 2019-2024 ( USD Billion )
  48. Asia Pacific Mode of action Market By Region, From 2019-2024 ( USD Billion )
  49. Asia Pacific Technology Market By Region, From 2019-2024 ( USD Billion )
  50. Asia Pacific Linker Market By Region, From 2019-2024 ( USD Billion )
  51. Asia Pacific Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  52. Asia Pacific Research institutes Market By Region, From 2019-2024 ( USD Billion )
  53. Asia Pacific Hospitals Market By Region, From 2019-2024 ( USD Billion )
  54. Asia Pacific Clinics Market By Region, From 2019-2024 ( USD Billion )
  55. Asia Pacific Others Market By Region, From 2019-2024 ( USD Billion )
  56. Japan Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  57. Japan Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  58. China Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  59. China Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  60. India Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  61. India Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  62. Australia Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  63. Australia Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  64. South Korea Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  65. South Korea Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  66. Latin America Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  67. Latin America Phase Market By Region, From 2019-2024 ( USD Billion )
  68. Latin America Mode of action Market By Region, From 2019-2024 ( USD Billion )
  69. Latin America Technology Market By Region, From 2019-2024 ( USD Billion )
  70. Latin America Linker Market By Region, From 2019-2024 ( USD Billion )
  71. Latin America Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  72. Latin America Research institutes Market By Region, From 2019-2024 ( USD Billion )
  73. Latin America Hospitals Market By Region, From 2019-2024 ( USD Billion )
  74. Latin America Clinics Market By Region, From 2019-2024 ( USD Billion )
  75. Latin America Others Market By Region, From 2019-2024 ( USD Billion )
  76. Brazil Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  77. Brazil Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  78. Argentina Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  79. Argentina Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  80. Mexico Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  81. Mexico Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  82. Rest of Latin America Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  83. Rest of Latin America Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  84. Middle East and Africa Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  85. Middle East and Africa Phase Market By Region, From 2019-2024 ( USD Billion )
  86. Middle East and Africa Mode of action Market By Region, From 2019-2024 ( USD Billion )
  87. Middle East and Africa Technology Market By Region, From 2019-2024 ( USD Billion )
  88. Middle East and Africa Linker Market By Region, From 2019-2024 ( USD Billion )
  89. Middle East and Africa Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  90. Middle East and Africa Research institutes Market By Region, From 2019-2024 ( USD Billion )
  91. Middle East and Africa Hospitals Market By Region, From 2019-2024 ( USD Billion )
  92. Middle East and Africa Clinics Market By Region, From 2019-2024 ( USD Billion )
  93. Middle East and Africa Others Market By Region, From 2019-2024 ( USD Billion )
  94. Middle East Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  95. Middle East Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  96. Africa Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  97. Africa Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample